Global Small Interfering Ribonucleic Acid (RNA) Industry Trends and Market Forecast 2026–2030
Uncover key drivers, emerging technologies, and competitive movements shaping the small interfering ribonucleic acid (rna) market from 2026–2035 with trusted insights from The Business Research Company
What level of CAGR-driven expansion is anticipated in the Small Interfering Ribonucleic Acid (RNA) Market between 2026 and 2030?
The market for small interfering ribonucleic acid (rna) has experienced significant expansion in recent years. This market is projected to expand from $18.86 billion in 2025 to $22.69 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 20.3%. Historically, this expansion has been driven by several key factors, including advancements in molecular biology research, an increasing prevalence of genetic and chronic diseases, the initial success of rna-based therapeutics, heightened research funding in genomics, and the establishment of rna interference mechanisms.
The small interfering ribonucleic acid (RNA) market size is expected to undergo substantial growth in the next few years, projected to reach $47.07 billion by 2030 with a compound annual growth rate (CAGR) of 20.0%. This growth during the forecast period can be attributed to increasing regulatory approvals for RNA therapies, rising demand for personalized medicine, the advancement of nanoparticle delivery innovations, growing investments from pharmaceutical companies, and the broader application of siRNA in treating infectious and rare diseases. Major trends identified for the forecast period include the increasing clinical adoption of RNA interference therapies, a growing focus on targeted gene silencing approaches, the expansion of advanced siRNA delivery platforms, rising investment in the development of precision therapeutics, and an enhanced emphasis on scalable RNA manufacturing processes.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=30394&type=smp
What Drivers Are Affecting Demand-Supply Dynamics In The Small Interfering Ribonucleic Acid (RNA) Market?
The increasing need for personalized medicine is anticipated to drive the expansion of the small interfering ribonucleic acid (RNA) market in the future. Personalized medicine refers to a healthcare strategy where treatments are customized for individual patients, considering their unique genetic makeup, environmental influences, and lifestyle choices to achieve better results and enhance care. The growing need for personalized medicine stems from progress in genomic technologies, allowing for accurate detection of genetic differences and the creation of specific treatments for individuals. Small interfering ribonucleic acid (siRNA) improves personalized medicine by facilitating targeted gene silencing, which makes it highly suitable for addressing particular genetic disorders and illnesses. By precisely suppressing disease-causing mRNA, it minimizes unintended side effects, thereby enhancing treatment effectiveness and patient results. As an illustration, in February 2024, data from the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, indicated that the U.S. Food and Drug Administration (FDA) cleared 26 new personalized medicines in 2023, marking a considerable rise from the 12 approved in 2022. Consequently, the increased demand for personalized medicine is fueling the expansion of the small interfering ribonucleic acid (RNA) market.
What Segments Are Included Within The Small Interfering Ribonucleic Acid (RNA) Market?
The small interfering ribonucleic acid (rna) market covered in this report is segmented –
1) By Type: Liposome Systemic Therapy, Nanoparticle-Based Systemic Therapy
2) By Indication: Cardiovascular Diseases, Respiratory Diseases, Oncology, Neurodegenerative Diseases, Infectious Diseases
3) By End-User: Hospital, Research Institutions, Pharmaceutical And Biotechnology Companies, Academic Institutions
Subsegments:
1) By Liposome Systemic Therapy: Cationic Liposome Delivery, Neutral Liposome Delivery, Pegylated Liposome Delivery, Targeted Liposome Delivery
2) By Nanoparticle-Based Systemic Therapy: Lipid Nanoparticle Delivery, Polymer Nanoparticle Delivery, Gold Nanoparticle Delivery, Silica Nanoparticle Delivery
What Trends Are Driving The Growth Trajectory Of The Small Interfering Ribonucleic Acid (RNA) Market?
Leading companies in the small interfering ribonucleic acid (siRNA) therapeutics market are prioritizing the attainment of regulatory approvals for innovative mechanisms aimed at treating rare genetic diseases, intending to offer sustained effects and reduce the dosing frequency for patients. Regulatory approvals signify official clearances from authorities that permit a drug or therapy to undergo safe testing, be marketed, or be administered to patients. For instance, in March 2025, Alnylam Pharmaceuticals Inc., a US-based biopharmaceutical company, secured approval from the U.S. Food and Drug Administration (FDA) for Qfitlia (fitusiran), which stands as the first small interfering ribonucleic acid (siRNA)-based therapy for adults and adolescents aged 12 years and older diagnosed with hemophilia A or B, whether or not they have inhibitors. This therapy is designed to lower antithrombin levels, thereby enhancing thrombin generation to encourage clot formation and minimize bleeding episodes. Qfitlia offers a subcutaneous, once-every-two-month dosing regimen, presenting a novel, non-factor therapeutic option for the management of hemophilia.
Who Are The Top-Performing Companies In The Small Interfering Ribonucleic Acid (RNA) Market In Recent Years?
Major companies operating in the small interfering ribonucleic acid (rna) market are Novartis AG, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Sanofi S.A., Sarepta Therapeutics Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Wave Life Sciences Ltd., Silence Therapeutics plc, Arrowhead Pharmaceuticals Inc., Quark Pharmaceuticals Inc., Arbutus Biopharma Corporation, Evox Therapeutics Ltd., Phio Pharmaceuticals Inc., Genecon Biotechnologies Co. Ltd., Olix Pharmaceuticals Inc., Benitec Biopharma Ltd., Bio-Path Holdings Inc., Calando Pharmaceuticals Inc., Sirnaomics Ltd.
Access The Complete Report For Deeper Market Insights:
Which Region Currently Holds The Largest Share Of The Small Interfering Ribonucleic Acid (RNA) Market?
North America was the largest region in the small interfering ribonucleic acid (RNA) market in 2025. The regions covered in the small interfering ribonucleic acid (rna) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Small Interfering Ribonucleic Acid (RNA) Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=30394&type=smp
Browse Through More Reports Similar to the Global Small Interfering Ribonucleic Acid (RNA) Market 2026, By The Business Research Company
Ribonucleic Acid Rna Sequencing Market Report 2026
Ribose Nucleic Acid Rna Based Therapeutics Market Report 2026
Nucleic Acid Isolation And Purification Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
